Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAPPA: Carfilzomib + pomalidomide + dexamethasone in relapsed/refractory multiple myeloma after carfilzomib + lenalidomide + dexamethasone
KCT0006285Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Amgen. Started Oct 2021; status: recruiting.
02
Drugs
carfilzomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0006285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006285.